Usted buscó: pbo (Inglés - Maltés)

pbo
jsn - djuq fl- ispazju tal- ġog * - p≤0. 0001, tcz vs.

pbo + mtx
pbo + mtx

bao and pbo
bao u pbo

pbo + dmar d
pbo + dmard

pbo + mtx/ dmard
pbo + mtx/ dmard

jsn score pbo mtx tcz jsn
punteġġ sharp- genant totali

determination of the combination bao + pbo
dożaġġ tal-kombinazzjoni bao + pbo

p < 0.001, t12/pr compared to pbo/pr48.
p < 0.001, t12/pr imqabbel ma’ pbo/pr48.

p < 0.0001; t12/pr compared to pbo/pr48.
p < 0.0001; t12/pr mqabbel ma’ pbo/pr48.

pbo + mtx/ dmard ** - p < 0.01, tcz vs.
pbo + mtx/ dmard ** - p < 0. 01, tcz vs.

table 15 shows the response rates for the t12/pr48 and the pbo/pr48 arms.
it-tabella 15 turi r-rati ta’ rispons għall-fergħat tal-kura t12/pr48 u pbo/pr48.

pbo/pr: placebo for 12 weeks with peginterferon alfa-2a and ribavirin for 48 weeks
pbo/pr: plaċebo għal 12-il ġimgħa b’peginterferon alfa-2a u ribavirin għal 48 ġimgħa

p < 0.001 for ustekinumab 45 mg or 90 mg in comparison with placebo (pbo).
p < 0.001 għal 45 mg jew 90 mg ustekinumab meta mqabbel ma’ plaċebo (pbo).

pbo/pr48: placebo for 16 weeks in combination with peginterferon alfa-2a and ribavirin for 48 weeks
pbo/pr48: plaċebo għal 16-il ġimgħa flimkien ma’ peginterferon alfa-2a u ribavirin għal 48 ġimgħa

for the purposes of subheadings 701322, 701333, 701341 and 701391, the expression ‘lead crystal’ means only glass having a minimum lead monoxide (pbo) content by weight of 24 %.
għall-għanijiet ta’ subtitli 701322, 701333, 701341 u 701391, l-espressjoni “kristall taċ-ċomb” tfisser biss ħġieġ b’kontenut minimu ta’ monossidu ta’ ċomb (pbo) ta’ 24 % bil-piż.